The Impact of Superoxide Dismutase-1 Genetic Variation on Cardiovascular and All-Cause Mortality in a Prospective Cohort Study: The Yamagata (Takahata) Study

Yoichiro Otaki¹, Tetsu Watanabe¹ *, Satoshi Nishiyama¹, Hiroki Takahashi¹, Takanori Arimoto¹, Tetsuro Shishido¹, Takuya Miyamoto¹, Tsuneo Konta¹, Yoko Shibata¹, Hidenori Sato², Ryo Kawasaki³, Makoto Daimon⁴, Yoshiyuki Ueno⁵, Takeo Kato⁵, Takamasa Kayama⁵, Isao Kubota¹

¹ Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine, Yamagata, Japan, 2 Genome Informatics Unit, Institute for Promotion of Medical Science Research, Faculty of Medicine, Yamagata University, Yamagata, Japan, 3 Department of Public Health, Graduate School of Medical Science, Yamagata University, Yamagata, Japan, 4 Department of Endocrinology and Metabolism, Hirosaki University Graduate School of Medicine, Aomori, Japan, 5 Global Center of Excellence Program Study Group, Yamagata University School of Medicine; Yamagata, Japan

* tewatana@med.id.yamagata-u.ac.jp

Abstract

Background

Oxidative stress is a major cause of cardiovascular disease. Superoxide dismutase-1 (SOD1) is an antioxidant that protects against oxidative stress. Deoxyribonucleic acid (DNA) variations such as single nucleotide polymorphism (SNP) or haplotypes within the SOD gene are reportedly associated with the development of cardiovascular disease. However, it remains to be determined whether SOD1 variability is associated with cardiovascular or all-cause mortality in the general population.

Methods and Results

This prospective cohort study included 2799 subjects who participated in a community-based health study with a 10-year follow-up. We genotyped 639 SNPs and found the association of SNP rs1041740 and rs17880487 within a SOD1 gene with cardiovascular mortality. There were 193 deaths during the follow-up period including 57 cardiovascular deaths. Multivariate Cox proportional hazard regression analysis revealed that the homozygous T-allele of rs1041740 was associated with all-cause and cardiovascular deaths after adjusting for confounding factors. The net reclassification index was significantly improved by adding rs1041740 as a cardiovascular risk factor. On the other hand, cardiovascular death was not observed in homozygous T-allele carriers of rs17880487. Haplotype analysis identified the haplotype with T-allele of rs1041740 and that with T-allele of rs17880487 as increasing and decreasing susceptibility for cardiovascular mortality, and it had complementary SNP sequences.
Conclusion
Variation in the SOD1 gene was associated with cardiovascular deaths in the general population.

Introduction
Despite advances in medicine, cardiovascular disease remains a major public health problem associated with high mortality [1,2]. The development of cardiovascular disease is associated with multiple genetic and cardiovascular risk factors. Single nucleotide polymorphism (SNP) is the most frequent type of human population deoxyribonucleic acid (DNA) variation and haplotype is defined as a combination of SNP alleles along a chromosome [3,4]. Whether DNA variation can be used to identify genes that increase the risk of cardiovascular disease is currently under discussion [5].

Oxidative stress is the excessive accumulation of reactive oxygen species (ROS) relative to antioxidant activity and is a major cause of cardiovascular disease [6,7]. Superoxide dismutase-1 (SOD1) is an antioxidant protein that plays a pivotal role in reducing ROS by catalysing superoxide into oxygen and hydrogen peroxide [8]. Previous reports demonstrated that some SOD1 SNPs are associated with the development of cardiovascular disease [9,10,11].

The present study examined whether SOD1 DNA variation can predict all-cause and cardiovascular mortality in the general population.

Methods
Ethics statement and study population
The institutional ethics committee of Yamagata University School of Medicine approved the study, and all participants provided written informed consent. The procedures were performed in accordance with the Helsinki Declaration.

Our analysis was part of a community-based health study of inhabitants in the town of Takahata in northern Japan (total population 26,026). Community members, aged >40 years were invited to participate in this study. In 2004 and 2005, 2,968 subjects (1,343 males and 1,625 females) were enrolled in the study but 169 subjects were excluded due to their incomplete data and study withdrawal.

Genotyping
Genotyping was performed with the Invader assay (Third Wave Technologies, Madison, WI, USA) and Taq Man Allelic discrimination assay. Reagents were purchased from Applied Biosystems (Foster City, CA, USA). Taq Man probes that can distinguish SNPs after polymerase chain reaction (PCR) were designed and synthesized by Applied Biosystems. One allelic probe was labelled with the fluorescent FAM dye, and the other with the fluorescent VIC dye. PCR was performed with the Taq Man Universal Master Mix with primers at concentrations of 225 nM and Taq Man MGB probes at concentrations of 50 nM. Reactions were performed in 382 well plates in a total volume of 3 μL using 3.0 ng genomic DNA. The plates were then placed in a GeneAmp PCR system 9700 (Applied Biosystems) and heated at 95°C for 10 min, followed by 40 cycles at 92°C for 15 sec and at 60°C for 1 min, with a final incubation at 25°C. The fluorescent intensities of each well in the plates were then read by the Prism 7900HTi instrument (Applied Biosystems). Fluorescent data files from each plate were analyzed with the SDS 2.0
allele calling software (Applied Biosystems). Several data points were eliminated to preserve the reliability of the assay system (missing data due to poor signal intensity < 1.1%) [12].

**Haplotype statistics**

Haplotype was identified according to the expectation maximization (EM) algorithm. Haplotypes with extremely low frequency were excluded from haplo.score analysis using R software. To examine the association of haplotype with cardiovascular mortality, haplo.scores were calculated. All haplotype analyses were performed with the haplo.stats plug in.

**Definition of cardiovascular risks**

Hypertension was defined as systolic blood pressure \( \geq 140 \) mmHg, diastolic blood pressure \( \geq 90 \) mmHg, or antihypertensive medication use. Diabetes mellitus (DM) was defined as having fasting blood glucose \( \geq 126 \) mg/dL, glycosylated hemoglobin A1c \( \geq 6.5\% \) (National Glycohemoglobin Standardization Program), or anti-diabetic medication use. Hyperlipidemia was defined as total cholesterol \( \geq 220 \) mg/dL, triglyceride \( \geq 150 \) mg/dL, or anti-hyperlipidemic medicine use. Family histories of cardiovascular disease and previous cardiovascular disease were determined by self-reported questionnaires. Framingham risk score was calculated according to previous report [13].

**Biochemical markers**

Blood samples were obtained to measure brain natriuretic peptide (BNP). These samples were transferred to chilled tubes containing 4.5 mg ethylene diamine tetra acetic acid disodium salt and aprotinin (500 U/mL), and centrifuged at 1,000 \( g \) for 15 minutes at 4°C. The clarified plasma samples were frozen, stored at -70°C, and thawed just before assay. BNP concentrations were measured using a commercially available radioimmunoassay specific for human BNP (Shiono RIA BNP assay kit, Shionogi Co. Ltd., Tokyo, Japan) [14].

Estimated glomerular filtration rate (eGFR) was calculated using the modification of diet in renal disease equation with the Japanese coefficient [15].

Total cholesterol, triglyceride, high density lipoprotein cholesterol, fasting blood glucose, and glycosylated hemoglobin A1c were also measured at the same time.

**Endpoint and follow-up**

All subjects were prospectively followed for a median period of 3,397 days (interquartile range, 3,097–3,443 days). The endpoint was all-cause death, which was further divided into cardiovascular and non-cardiovascular death. Cardiovascular death was defined as death due to coronary artery disease, heart failure, arrhythmia, stroke, or aortic artery disease. The cause of death was determined by reviewing death certificates through the end of 2014. The death code (International Classification of Diseases, 10th Revision) and place of death were reviewed.

**Statistical analysis**

Continuous variable normality was checked with a Kolmogorov-Smirnov-Lillefors test. Because BNP was not normally distributed, we used log\(_e\) BNP for all analyses. All values are expressed as the mean ± standard deviation. Continuous and categorical variables were compared with t-tests and chi-square tests, respectively. Differences among SOD1 genetic variations were assessed with analysis of variance (ANOVA) with Bonferroni post hoc tests. A Cox proportional hazard analysis was performed to determine independent predictors for all-cause deaths, cardiovascular deaths, and non-cardiovascular deaths, and cardiovascular risk factors.
were entered into the multivariate analysis. We calculated the net reclassification index (NRI) and integrated discrimination index (IDI) to measure the quality of improvement for the correct reclassification according to the addition of SNPs within SOD1 to the multivariate model. Survival curves were constructed with the Kaplan-Meier method and compared using log-rank tests. P < 0.05 was considered statistically significant. All statistical analyses were performed with standard statistical program packages (JMP version 11; SAS Institute Inc., Cary, NC, USA and R 3.0.2 with additional packages including Rcmdr, Epi, pROC, and PredictABEL).

**Results**

**Baseline characteristics and clinical characteristics related SNP rs1041740**

The Yamagata study protocol and the genotyped SNPs within SOD1 are shown in Fig 1. During the follow-up period, there were 193 all-cause deaths including 57 cardiovascular and 136 non-cardiovascular deaths. We found the association of SOD1 SNP with cardiovascular mortality using in silico analysis from the 639 SNPs examined in this study. The homozygous T-allele (TT), heterozygous (TC), and homozygous C-allele (CC) carriers of rs1041740 were identified.

![Diagram](image)

**Fig 1.** The study protocol (A) and polymorphism in SOD1 gene examined in the study (B). Chr, chromosome; SNP, single nucleotide polymorphism; SOD, superoxide dismutase; UTR, untranslated region.

doi:10.1371/journal.pone.0164732.g001
in 307 (11%), 1,259 (45%), and 1,233 (44%) subjects, respectively. Also, TT, TC, and CC carriers of rs17880487 were identified in 29 (1%), 465 (17%), and 2,305 (82%), respectively. As shown in Table 1, rs1041740 TT carriers had a higher BNP level compared to other groups. Moreover, rs1041740 TT carriers had a greater family history of cardiovascular disease compared to the rs1041740 CC carriers. There were no significant differences in age, gender, or prevalence rates of previous cardiovascular disease, smoking, hypertension, DM, or hyperlipidemia among rs1041740 genotypes. The rs1041740 TT carriers did not overlap the rs17880487 TT carriers.

Clinical characteristics related to rs17880487 were shown in S1 Text. Interestingly, the rs17880487 TT carriers had a lower prevalence of family history of cardiovascular disease compared to rs17880487 TC and CC carriers. Cardiovascular death was not observed in Table 1. Baseline and clinical characteristics among rs1041740 genotypes.

| Variables                        | All subject n = 2799 | Homozygous C-allele carriers n = 1233 | Heterozygous carriers n = 1259 | Homozygous T-allele carriers n = 307 |
|----------------------------------|----------------------|---------------------------------------|-------------------------------|-------------------------------------|
| Age, years                       | 63 ± 10              | 63 ± 10                               | 63 ± 10                       | 64 ± 10                             |
| Male/female, n                   | 1270/1529            | 556/677                               | 562/697                       | 152/155                             |
| Family history of cardiovascular disease, n (%) | 476 (17%)           | 178 (14%)                             | 241 (19%)                     | 57 (19%)#                           |
| Previous CVD, n (%)             | 383 (14%)            | 149 (12%)                             | 187 (15%)                     | 47 (15%)                            |
| Previous cancer, n (%)          | 55 (2.0%)            | 23 (1.8%)                             | 27 (2.1%)                     | 5 (1.6%)                            |
| Smoking, n (%)                  | 906 (32%)            | 398 (32%)                             | 400 (32%)                     | 108 (35%)                           |
| Hypertension, n (%)             | 1038 (37%)           | 446 (36%)                             | 477 (38%)                     | 115 (37%)                           |
| Diabetes mellitus, n (%)        | 191 (7%)             | 92 (7.5%)                             | 82 (6.5%)                     | 17 (5.5%)                           |
| Hyperlipidemia, n (%)           | 1044 (37%)           | 479 (39)                              | 454 (36)                      | 111 (36)                            |
| Systolic BP, mmHg               | 134 ± 16             | 134 ± 16                              | 134 ± 16                      | 135 ± 16                            |
| Diastolic BP, mmHg              | 79 ± 10              | 79 ± 10                               | 79 ± 10                       | 79 ± 10                             |
| HbA1c, %                        | 5.6 ± 0.7            | 5.7 ± 0.7                              | 5.6 ± 0.7                     | 5.6 ± 0.5                           |
| FBG, mg/dL                      | 94 ± 17              | 95 ± 18                               | 93 ± 16                       | 94 ± 16                             |
| TC, mg/dL                       | 201 ± 31             | 201 ± 32                              | 200 ± 31                      | 200 ± 32                            |
| HDLc, mg/dL                     | 59 ± 14              | 59 ± 14                               | 59 ± 14                       | 60 ± 15                             |
| TG, mg/dL                       | 106 ± 64             | 107 ± 62                              | 104 ± 65                      | 107 ± 66                            |
| eGFR, mL/min/1.73 m²            | 81 ± 16              | 82 ± 16                               | 80 ± 16                       | 83 ± 18†                            |
| Log_{10} BNP, pg/mL             | 3.02 ± 0.83          | 3.00 ± 0.83                           | 3.00 ± 0.83                   | 3.14 ± 0.88*†                       |
| Framingham risk score           | 14 ± 4               | 14 ± 4                                | 14 ± 4                        | 14 ± 4                              |
| SNP SOD gene                    | rs2070424, AA/AG/GG  | 644/1433/722                          | 58/454/721                    | 279/979/1                           | 307/0/0                             |
|                                 | rs4998557, AA/AG/GG  | 720/1433/646                          | 720/454/59                    | 0/979/280                          | 0/0/307                             |
|                                 | rs1041740, CC/CT/TT  | 1233/1259/307                         | 1233/0/0                      | 0/1259/0                           | 0/0/307                             |
|                                 | rs4817420, CC/CT/TT  | 1233/1259/307                         | 1233/0/0                      | 0/1259/0                           | 0/0/307                             |
|                                 | rs17880487, CC/CT/TT | 2305/465/29                           | 911/293/29                    | 1087/172/0                         | 307/0/0                             |

Data are expressed as mean ± standard deviation or number (%)

BNP, brain natriuretic peptide; BP, blood pressure; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; FBG, fasting blood glucose; HbA1c, glycosylated hemoglobin A1c; HDLc, high density lipoprotein cholesterol; SNP, single nucleotide polymorphism; SOD, superoxide dismutase; TC, total cholesterol; TG, triglyceride.

* p < 0.05 vs. homozygous C-allele carriers
† p < 0.05 vs. heterozygous carriers by analysis of variance (ANOVA) with Bonferroni test.
* p < 0.05 by chi-square test.

doi:10.1371/journal.pone.0164732.t001
rs17880487 TT carriers. The impact of rs1041740 TT carriers and rs17880487 TT carriers on the cardiovascular disease was shown in S1 Fig.

All-cause and cardiovascular mortality and SNP rs1041740
As shown in Fig 2A, univariate Cox proportional hazard regression analysis demonstrated that the homozygous T-allele of rs1041740 was related to all-cause deaths and cardiovascular deaths in the general population. On the other hand, it was not related to non-cardiovascular deaths. To determine the risk factors associated with all-cause deaths, cardiovascular deaths, and non-cardiovascular deaths, cardiovascular risk factors were entered into the multivariate Cox proportional hazard model. It demonstrated that the homozygous T-allele of rs1041740 was an independent predictor of future all-cause and cardiovascular mortality (all-cause deaths, adjusted hazard ratio, 1.53; 95% confidence interval, 1.01–2.30; P = 0.0445 and cardiovascular deaths, adjusted hazard ratio, 2.07; 95% confidence interval, 1.10–3.91; P = 0.0244; Fig 2B).

Kaplan-Meier analysis demonstrated that rs1041740 TT carriers had a higher rate of all-cause and cardiovascular mortality compared to rs1041740 TC and CC carriers (Fig 3).

![Fig 2. Univariate (A) and multivariate (B) Cox proportional hazard regression analyses for mortality. *after adjustment for age, gender, family history of cardiovascular disease, previous cardiovascular disease, smoking, hypertension, diabetes mellitus, hyperlipidemia, total cholesterol, high density lipoprotein cholesterol, systolic blood pressure, BNP, and eGFR. #after adjustment for age, gender, BNP, eGFR, and Framingham risk score. BNP, brain natriuretic peptide; CI, confidence interval; eGFR, estimated glomerular filtration rate. doi:10.1371/journal.pone.0164732.g002](image-url)
Subgroup analysis in subjects without previous cardiovascular disease

Next, we performed subgroup analysis in subjects without previous cardiovascular disease to examine whether homozygous T-allele of rs1041740 could also predict cardiovascular mortality in these populations. As shown in Fig 4A, univariate Cox proportional hazard regression analysis demonstrated that the homozygous T-allele of rs1041740 was related to cardiovascular deaths in the general population. To determine the risk factors associated with cardiovascular deaths, age, gender, and Framingham risk score were entered into the multivariate Cox proportional hazard model. It demonstrated that the homozygous T-allele of rs1041740 was an independent predictor of cardiovascular mortality (adjusted hazard ratio, 2.13; 95% confidence interval, 1.02–4.45; P = 0.0440; Fig 4A).

Kaplan-Meier analysis demonstrated that rs1041740 TT carriers had a higher rate of cardiovascular mortality compared to rs1041740 TC and CC carriers (Fig 4B).

Improvement of reclassification by adding SOD1 SNP rs1041740 to predict all-cause and cardiovascular mortality

To examine whether model fit and discrimination improve when the SOD1 SNP rs1041740 was added to the known predictors of age, gender, family history of cardiovascular disease, previous cardiovascular disease, smoking, DM, eGFR, BNP, and Framingham risk score, we evaluated improvements in the NRI and IDI. As shown in Table 2, NRI and IDI to predict cardiovascular mortality was significantly improved by adding the SOD1 SNP rs1041740 (Table 2).

SOD1 haplotype and cardiovascular mortality

As shown in Table 3, nine haplotypes were identified in the study population. The sequence in haplotype 2 was GATTC, including the minor T-allele of rs1041740. The sequence in
haplotype 4 was AGCCT, including the minor T-allele of rs17880487, indicating that these haplotypes had complementary SNP sequences. To examine whether SOD1 haplotype is related to cardiovascular mortality, the haplo.score was calculated, and the results suggested that haplotypes 2 and 4 confer susceptibility and protection for cardiovascular mortality, respectively (Haplotype 2 haplo.score, 1.9912, P = 0.0465; haplotype 4 haplo.score, -2.13818, P = 0.0325).

Fig 4. (A) Multivariate Cox proportional hazard regression analyses for cardiovascular mortality in subjects without previous cardiovascular disease. After adjustment for age, gender, and Framingham risk score. CI, confidence interval. (B) Kaplan-Meier analysis of cardiovascular deaths among rs1041740 genotype in subjects without previous cardiovascular disease.

doi:10.1371/journal.pone.0164732.g004

Table 2. Statistics for model fit and improvement with the addition of rs1041740 on the prediction of cardiovascular mortality.

| NRI (95% CI, P value) | IDI (95% CI, P value) |
|-----------------------|-----------------------|
| Baseline model        | Reference             | Reference             |
| +rs1041740            | 0.1084 (0.0101–0.2068, P = 0.0308) | 0.0151 (0.0001–0.0301, P = 0.0492) |

Baseline model includes age, gender, family history of cardiovascular disease, previous cardiovascular disease, smoking, diabetes mellitus, estimated glomerular filtration rate, brain natriuretic peptide, and Framingham risk score. 95%CI, 95% confidence interval; NRI, net reclassification index; IDI, integrated discrimination index.

doi:10.1371/journal.pone.0164732.t002
Discussion

Main findings

The results of this study revealed that the rs1041740 TT carriers in the SOD1 gene had a higher level of BNP and a more frequent family history of cardiovascular disease compared to TC and CC carriers. Subjects with the rs1041740 TT genotype were at higher risk of all-cause and cardiovascular mortality; these associations were significant even after adjustments in a multivariate model with other known risk factors. Adding the rs1041740 TT genotype with known risk factors to the model enhanced the predictive capacity of cardiovascular mortality as NRI and IDI were significantly improved. We also identified protective and susceptible SOD1 haplotypes for cardiovascular mortality.

Family history of cardiovascular mortality and DNA variation of SOD1

A family history of cardiovascular disease is considered to be a risk factor for cardiovascular disease since it was reported to be closely associated with the development of cardiovascular disease [16,17]. Since inherited DNA sequence variants were suggested to play a causal role in cardiovascular disease susceptibility, SNP has been noted to explain the inherited cardiovascular disease [18]. In the present study, we showed that rs1041740 TT carriers had a higher prevalence of family history compared with rs1041740 CC carriers. On the other hand, rs17880487 TT carriers had no family history of cardiovascular disease. Although family history examined by self-reported questionnaires often includes recall bias, these results raised the possibility that DNA variation of SOD1 contribute to cardiovascular disease heritability.

BNP and rs1041740

BNP is a diagnostic marker for heart failure, that is constitutively synthesized and secreted from cardiomyocytes [19]. BNP levels are reportedly affected by several factors such as aging, gender, body mass index, and kidney function [20,21,22,23]. In the present study, the homozygous T-allele of rs1041740 carriers had a higher level of BNP compared to other groups despite similar levels of these factors. BNP expression is also reported to be increased in the several conditions such as left ventricular mechanical stretch, inflammation, and oxidative stress [24], suggesting that DNA variation of SOD1 modulated BNP expression in the general population. Previous studies have reported that BNP is a useful indicator of all-cause and cardiovascular deaths in the general population [25]. The results described here supported our hypothesis that genetic variation of SOD1 is a risk for cardiovascular mortality.

Table 3. Haplotype sequence, frequency, and hap score in SOD1 haplotypes.

| Haplotype | rs4998557 | rs2070424 | rs1041740 | rs4817420 | rs17880487 | Frequency | Hap score | P value |
|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|--------|
| 1         | A         | G         | C         | C         | C         | 0.41956   | -0.35348  | 0.7237 |
| 2         | G         | A         | T         | T         | C         | 0.33439   | 1.9912    | 0.0465 |
| 3         | G         | A         | C         | C         | C         | 0.15132   | -0.33304  | 0.7391 |
| 4         | A         | G         | C         | C         | T         | 0.09330   | -2.13818  | 0.0325 |
| 5         | G         | G         | C         | C         | C         | 0.00008   |          |        |
| 6         | A         | A         | C         | C         | C         | 0.00023   |          |        |
| 7         | G         | G         | T         | T         | C         | 0.00020   | -0.31975  | 0.7492 |
| 8         | A         | A         | C         | C         | T         | 0.00013   |          |        |
| 9         | G         | G         | C         | C         | T         | 0         |          |        |

SOD, superoxide dismutase.

doi:10.1371/journal.pone.0164732.t003
DNA variation of SOD1 and mortality

No prospective study has examined the impact of SOD1 DNA variation on all-cause and cardiovascular mortality in the general population. Previous reports concluded that the minor T-allele of rs1041740 is a risk for future cardiovascular mortality in patients with DM [26,27]. Similarly, we showed that the allele variation in SOD1 is associated with all-cause and cardiovascular mortality in the general population. Although the SNPs examined in the present study were located in the intron or 3′-untranslated region, haplotype analysis showed that there were susceptible and protective haplotypes for cardiovascular mortality and they had complementary SNP sequences. Previous reports raised the possibility that DNA variation in these regions regulates gene expression by influencing transcription and translation processes [28,29]. Experimental studies have demonstrated that SOD1 works as an antioxidant and protects cardiomyocytes from oxidative stress in a myocardial infarction model [30,31]. Interestingly, SNP within SOD1 was the independent predictor of cardiovascular deaths after adjustment for cardiovascular risk factors. The genetic variation of SOD1 may deteriorate cardiovascular mortality through reduced SOD1 expression and activity with resultant increase in oxidative stress. Considering the role of SOD1, it is possible that variation in the gene encoding this protein is related to cardiovascular disease hereditability.

Limitation

The strengths of this study are that it was conducted with a large number of participants and had a long follow-up period. However, there are some limitations. First, this study collected baseline information at a single time point. Subsequent medical interventions may have affected serum BNP levels. Second, non-fatal diseases were not assessed, which could result in an underestimation of the association between SNPs within SOD1 and clinical outcomes. Third, a missense mutation of SOD1 is associated with the development of amyotrophic lateral sclerosis [32]. Taking the role of SNPs used in the present study into account, it is unlikely that these SNPs induce amyotrophic lateral sclerosis. Finally, protein expression and activity of SOD1 and oxidative stress markers were not measured.

Conclusions

SOD1 variation was found to be associated with cardiovascular mortality in the general population. This knowledge may improve re-classification beyond known risk factors and underlies the importance of cardiovascular disease hereditability.

Supporting Information

S1 Fig. The association between DNA variation and family history of cardiac disease (A) and cardiovascular deaths (B). TT, homozygous T-allele carriers; TC, heterozygous carriers; CC, homozygous C-allele carriers.

S1 Text. Clinical characteristics related SNP rs17880487.

Author Contributions

Conceptualization: YO TW.
Data curation: YU T. Kato T. Kayama IK.
Formal analysis: YO TW YS T. Konta HS RK.

Funding acquisition: YU T. Kato T. Kayama IK.

Investigation: YO TW MD.

Methodology: YO TW HS RK MD.

Project administration: YU T. Kato T. Kayama IK.

Resources: MD YU T. Kato T. Kayama IK.

Supervision: TW.

Validation: YU T. Kato T. Kayama IK.

Visualization: YO.

Writing – original draft: YO TW HS RK.

Writing – review & editing: SN HT TA TS TM.

References

1. Chen J, Normand SL, Wang Y, Krumholz HM (2011) National and regional trends in heart failure hospitalization and mortality rates for Medicare beneficiaries, 1998–2008. JAMA 306: 1669–1678. doi: 10.1001/jama.2011.1474 PMID: 22009099

2. Lloyd-Jones DM, Larson MG, Leip EP, Beiser A, D’Agostino RB, Kannel WB, et al. (2002) Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation 106: 3068–3072. PMID: 12473553

3. Gray IC, Campbell DA, Spurr NK (2000) Single nucleotide polymorphisms as tools in human genetics. Hum Mol Genet 9: 2403–2408. PMID: 11005795

4. McCarthy JJ, Hilfiker R (2000) The use of single-nucleotide polymorphism maps in pharmacogenomics. Nat Biotechnol 18: 505–508. doi: 10.1038/75360 PMID: 10802616

5. Kao SL, Chong SS, Lee CG (2000) The role of single nucleotide polymorphisms (SNPs) in understanding complex disorders and pharmacogenomics. Ann Acad Med Singapore 29: 376–382. PMID: 10976393

6. Hare JM (2001) Oxidative stress and apoptosis in heart failure progression. Circ Res 89: 198–200. PMID: 11485698

7. Burgoyne JR, Mongue-Din H, Eaton P, Shah AM (2012) Redox signaling in cardiac physiology and pathology. Circ Res 111: 1091–1106. doi: 10.1161/CIRCRESAHA.111.259216 PMID: 23023511

8. Fridovich I (1995) Superoxide radical and superoxide dismutases. Annu Rev Biochem 64: 97–112. doi: 10.1146/annurev.bi.64.070195.000525 PMID: 7574505

9. Charniot JC, Sutton A, Bonnefont-Rousselot D, Cosson C, Khani-Bittar R, Giral P, et al. (2011) Manganese superoxide dismutase dimorphism relationship with severity and prognosis in cardiogenic shock due to dilated cardiomyopathy. Free Radic Res 45: 379–388. doi: 10.3109/10715762.2010.532792 PMID: 21062213

10. Jones DA, Prior SL, Tang TS, Bain SC, Hurel SJ, Humphries SE, et al. (2010) Association between the rs4880 superoxide dismutase 2 (C>T) gene variant and coronary heart disease in diabetes mellitus. Diabetes Res Clin Pract 90: 196–201. doi: 10.1016/j.diabres.2010.07.009 PMID: 20728955

11. Kakkio S, Paivansalo M, Koistinen P, Kesaniemi YA, Kinnula VL, Savolainen MJ (2003) The signal sequence polymorphism of the MnSOD gene is associated with the degree of carotid atherosclerosis. Atherosclerosis 168: 147–152. PMID: 12732398

12. Takeishi Y, Toriyama S, Takahashi N, Shibata Y, Konta T, Emi M, et al. (2007) Linkage disequilibrium analyses of natriuretic peptide precursor B locus reveal risk haplotype conferring high plasma BNP levels. Biochem Biophys Res Commun 362: 480–484. doi: 10.1016/j.bbrc.2007.08.028 PMID: 17719005

13. D’Agostino RB Sr, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, et al. (2008) General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 117: 743–753. doi: 10.1161/CIRCULATIONAHA.107.699579 PMID: 18212285

14. Otaki Y, Watanabe T, Takahashi H, Hirayama A, Narumi T, Kadowaki S, et al. (2014) Association of heart-type Fatty Acid-binding protein with cardiovascular risk factors and all-cause mortality in the...
15. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. (2009) Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 53: 982–992. doi: 10.1053/j.ajkd.2008.12.034 PMID: 19339088

16. Bachmann JM, Willis BL, Ayers CR, Khera A, Berry JD (2012) Association between family history and coronary heart disease death across long-term follow-up in men: the Cooper Center Longitudinal Study. Circulation 125: 3092–3098. doi: 10.1161/CIRCULATIONAHA.111.065490 PMID: 22623718

17. Lind C, Enga KF, Mathiesen EB, Njolstad I, Braekkan SK, Hansen JB (2014) Family history of myocardial infarction and cause-specific risk of myocardial infarction and venous thromboembolism: the Tromso Study. Circ Cardiovasc Genet 7: 684–691. doi: 10.1161/CIRCGENETICS.114.000621 PMID: 25087051

18. Musunuru K, Kathiresan S (2008) HapMap and mapping genes for cardiovascular disease. Circ Cardiovasc Genet 1: 66–71. doi: 10.1161/CIRCGENETICS.108.813675 PMID: 20031544

19. Tsutamoto T, Wada A, Maeda K, Hisanaga T, Maeda Y, Fukai D, et al. (1997) Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation 96: 509–516. PMID: 9244219

20. Christenson RH, Azzazy HM, Duh SH, Maynard S, Seliger SL, Defilippi CR (2010) Impact of increased body mass index on accuracy of B-type natriuretic peptide (BNP) and N-terminal proBNP for diagnosis of decompensated heart failure and prediction of all-cause mortality. Clin Chem 56: 633–641. doi: 10.1373/clinchem.2009.129742 PMID: 20167699

21. Kawai M, Yoshimura M, Harada M, Mizuno Y, Hiramitsu S, Shimizu M, et al. (2013) Determination of the B-type natriuretic peptide level as a criterion for abnormalities in Japanese individuals in routine clinical practice: the J-ABS Multi-Center Study (Japan Abnormal BNP Standard). Intern Med 52: 171–177. PMID: 23318945

22. Kara K, Mahabadi AA, Geisel MH, Lehmann N, Kalsch H, Bauer M, et al. (2014) B-type natriuretic peptide: distribution in the general population and the association with major cardiovascular and coronary events—the Heinz Nixdorf Recall Study. Clin Res Cardiol 103: 125–132. doi: 10.1007/s00392-013-0628-4 PMID: 24126437

23. van Kimmenade RR, Januzzi J Jr, Bakker JA, Houben AJ, Rennenberg R, Kroon AA, et al. (2009) Renal clearance of B-type natriuretic peptide and amino terminal pro-B-type natriuretic peptide a mechanistic study in hypertensive subjects. J Am Coll Cardiol 53: 884–890. doi: 10.1016/j.jacc.2008.11.032 PMID: 19264247

24. LaPointe MC (2005) Molecular regulation of the brain natriuretic peptide gene. Peptides 26: 944–956. doi: 10.1016/j.peptides.2004.08.028 PMID: 15911064

25. Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Omland T, et al. (2004) Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 350: 655–663. doi: 10.1056/NEJMoa031994 PMID: 14960742

26. Mohammadi K, Maimaitiming S, Emery N, Bellili-Munoz N, Roussel R, Fumeron F, et al. (2011) Allelic variations in superoxide dismutase-1 (SOD1) gene are associated with increased risk of diabetic nephropathy in type 1 diabetic subjects. Mol Genet Metab 104: 654–660. doi: 10.1016/j.ymgme.2011.08.033 PMID: 21963083

27. Neves AL, Mohammed K, Emery N, Roussel R, Fumeron F, Marre M, et al. (2012) Allelic variations in superoxide dismutase-1 (SOD1) gene and renal and cardiovascular morbidity and mortality in type 2 diabetic subjects. Mol Genet Metab 106: 359–365. doi: 10.1016/j.ymgme.2012.04.023 PMID: 22608880

28. Wang L, Yi R (2014) 3’UTRs take a long shot in the brain. Bioessays 36: 39–45. doi: 10.1002/bies.201300100 PMID: 24110548

29. Greenwood TA, Kelsoe JR (2003) Promoter and intronic variants affect the transcriptional regulation of the human dopamine transporter gene. Genomics 82: 511–520. PMID: 14559208

30. Gao J, Zhong MK, Fan ZD, Yuan N, Zhou YB, Gao XY, et al. (2012) SOD1 overexpression in paraventricular nucleus improves post-infarct myocardial remodeling and ventricular function. Pflugers Arch 463: 297–307. doi: 10.1007/s00424-011-1036-0 PMID: 22006090

31. Zhang YE, Fu SZ, Li XQ, Chen P, Wang JL, Che J, et al. (2011) PEP-1-SOD1 protects brain from ischemic insult following asphyxial cardiopulmonary arrest in rats. Resuscitation 82: 1081–1086. doi: 10.1016/j.resuscitation.2011.01.034 PMID: 21531066

32. Boilee S, Vande Velde C, Cleveland DW (2006) ALS: a disease of motor neurons and their nonneuronal neighbors. Neuron 52: 39–59. doi: 10.1016/j.neuron.2006.09.018 PMID: 17015226